AAAAAA

   
Results: 1-25 | 26-37 |
Results: 26-37/37
CHEMOTHERAPY-INDUCED HIGH-MOLECULAR-WEIGHT DNA-DEGRADATION AND PROGRAMMED CELL-DEATH IS INHIBITED BY BCL-2 IN NEUROBLASTOMA-CELLS
Authors: DOLE MG NUNEZ G MERCHANT A MAYBAUM J RODE C BLOCH CA CASTLE VP
Citation: Mg. Dole et al., CHEMOTHERAPY-INDUCED HIGH-MOLECULAR-WEIGHT DNA-DEGRADATION AND PROGRAMMED CELL-DEATH IS INHIBITED BY BCL-2 IN NEUROBLASTOMA-CELLS, Pediatric research, 35(4), 1994, pp. 10000160-10000160
THE BCL-2 ONCOGENE IS A NOVEL PROGNOSTIC MARKER FOR NEUROBLASTOMA ANDCONFERS RESISTANCE TO CHEMOTHERAPY
Authors: NUNEZ G DOLE MG HEIDELBERGER KP CASTLE VP
Citation: G. Nunez et al., THE BCL-2 ONCOGENE IS A NOVEL PROGNOSTIC MARKER FOR NEUROBLASTOMA ANDCONFERS RESISTANCE TO CHEMOTHERAPY, Laboratory investigation, 70(1), 1994, pp. 10000147-10000147
BCL-X(L) A GENE WHICH REGULATES PROGRAMMED CELL-DEATH, IS EXPRESSED IN NEUROBLASTOMA TUMOR-CELL LINES
Authors: JASTY R DOLE M COOPER MJ NUNEZ G CASTLE VP
Citation: R. Jasty et al., BCL-X(L) A GENE WHICH REGULATES PROGRAMMED CELL-DEATH, IS EXPRESSED IN NEUROBLASTOMA TUMOR-CELL LINES, Clinical research, 42(3), 1994, pp. 10000416-10000416
BCL-2 INHIBITS CHEMOTHERAPY-INDUCED APOPTOSIS IN NEUROBLASTOMA
Authors: DOLE M NUNEZ G MERCHANT AK MAYBAUM J RODE CK BLOCH CA CASTLE VP
Citation: M. Dole et al., BCL-2 INHIBITS CHEMOTHERAPY-INDUCED APOPTOSIS IN NEUROBLASTOMA, Cancer research, 54(12), 1994, pp. 3253-3259
LINEAGE SWITCH IN PHILADELPHIA-CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA
Authors: REARDON DA HANSON CA ROTH MS CASTLE VP
Citation: Da. Reardon et al., LINEAGE SWITCH IN PHILADELPHIA-CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA, Cancer, 73(5), 1994, pp. 1526-1532
FAILURE TO INDUCE P53 AS A MECHANISM FOR RADIATION-RESISTANCE IN NEUROBLASTOMA
Authors: JASTY R DOLE M CLARKE MF CASTLE VP
Citation: R. Jasty et al., FAILURE TO INDUCE P53 AS A MECHANISM FOR RADIATION-RESISTANCE IN NEUROBLASTOMA, Blood, 84(10), 1994, pp. 10000299-10000299
BCL-XL AND BCLX-S MODULATE APOPTOSIS IN NEUROBLASTOMA
Authors: DOLE MG EIPERS P JASTY R CLARKE MF COOPER M NUNEZ G CASTLE VP
Citation: Mg. Dole et al., BCL-XL AND BCLX-S MODULATE APOPTOSIS IN NEUROBLASTOMA, Blood, 84(10), 1994, pp. 10000373-10000373
CONFIRMING FACTOR-XIII DEFICIENCY - COMPARISON OF 3 NEWER ASSAY METHODOLOGIES
Authors: DANIELS TM FISHER PK MALLOUH AA CASTLE VP BOWIE EJW NICHOLS WL
Citation: Tm. Daniels et al., CONFIRMING FACTOR-XIII DEFICIENCY - COMPARISON OF 3 NEWER ASSAY METHODOLOGIES, Thrombosis and haemostasis, 69(6), 1993, pp. 1293-1293
DEREGULATED EXPRESSION OF BCL-2 CONFERS CHEMOTHERAPY RESISTANCE TO THE NEUROBLASTOMA CELL-LINE SHEP-1
Authors: DOLE M NUNEZ G CASTLE VP
Citation: M. Dole et al., DEREGULATED EXPRESSION OF BCL-2 CONFERS CHEMOTHERAPY RESISTANCE TO THE NEUROBLASTOMA CELL-LINE SHEP-1, Clinical research, 41(3), 1993, pp. 10000625-10000625
THE TRANSFORMING POTENTIAL OF THROMBOSPONDIN RESIDES IN A 449 AMINO-ACID N-TERMINAL PEPTIDE
Authors: CASTLE VP OU XG DIXIT VM
Citation: Vp. Castle et al., THE TRANSFORMING POTENTIAL OF THROMBOSPONDIN RESIDES IN A 449 AMINO-ACID N-TERMINAL PEPTIDE, Clinical research, 41(3), 1993, pp. 10000672-10000672
BCL-2 ONCOGENE EXPRESSION CONFERS CHEMOTHERAPY RESISTANCE TO NEUROBLASTOMA-CELLS
Authors: DOLE MG NUNEZ G CASTLE VP
Citation: Mg. Dole et al., BCL-2 ONCOGENE EXPRESSION CONFERS CHEMOTHERAPY RESISTANCE TO NEUROBLASTOMA-CELLS, Blood, 82(10), 1993, pp. 10000121-10000121
EXPRESSION OF THE APOPTOSIS-SUPPRESSING PROTEIN BCL-2, IN NEUROBLASTOMA IS ASSOCIATED WITH UNFAVORABLE HISTOLOGY AND N-MYC AMPLIFICATION
Authors: CASTLE VP HEIDELBERGER KP BROMBERG J OU XG DOLE M NUNEZ G
Citation: Vp. Castle et al., EXPRESSION OF THE APOPTOSIS-SUPPRESSING PROTEIN BCL-2, IN NEUROBLASTOMA IS ASSOCIATED WITH UNFAVORABLE HISTOLOGY AND N-MYC AMPLIFICATION, The American journal of pathology, 143(6), 1993, pp. 1543-1550
Risultati: 1-25 | 26-37 |